Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The incidence of gluten-related disorders (GRDs) continues to increase and its global prevalence is estimated affect to 5% of the population. s. Celiac disease (CD), Dermatitis Herpetiformis (DH), Gluten Ataxia (GA), wheat allergy (WA), and Non-Celiac Gluten Sensitivity (NCGS) are the five major GRDs that present with a wide range of clinical manifestations. They are manifested by symptoms of gastrointestinal tract disorders, as well as hematological, dermatological endocrinological, gynecological, rheumatological and nervous system. NCGS is a term that is used to describe individuals who are not affected by celiac disease or wheat allergy, yet they have intestinal and/or extra-intestinal symptoms related to gluten ingestion with improvement of their symptoms upon withdrawing gluten from their diet. It is believed that represents some heterogeneous groups with different subgroups characterized by different etiologies, clinical histories and clinical courses. There also appears to be an overlap between NCGS and irritable bowel syndrome (IBS). There is a need for establishing strict criteria for diagnosing NCGS. The absence of validated biomarkers remains a significant limitation for research studies on NCGS. New evidence shows that a gluten-free diet may be beneficial for some patients with gastrointestinal symptoms, such as those symptoms commonly found in patients with IBS.

Medicine --- celiac disease --- children --- HLA-DQ --- prevalence --- Asia --- wheat --- gluten --- non-celiac gluten-sensitivity --- diagnosis --- dermatitis herpetiformis --- anti-tTG --- anti-DGP --- AAA --- AGA --- IL-17A --- HLA-DQB1*02 --- screening --- first-degree relatives --- non-celiac gluten sensitivity --- irritable bowel disease --- FODMAP --- wheat allergy --- vitamin B12 --- iron --- folic acid --- vitamin D --- long-term GFD therapy (LTGFD) --- LTGFD with good compliance (LTGFDWGC) --- anemia --- lymphoma --- IgA deficiency --- gut --- enteropathy --- gluten-free diet --- level of evidences --- gluten-related disorders --- NCGS --- self-report --- survey studies --- celiac disease --- children --- HLA-DQ --- prevalence --- Asia --- wheat --- gluten --- non-celiac gluten-sensitivity --- diagnosis --- dermatitis herpetiformis --- anti-tTG --- anti-DGP --- AAA --- AGA --- IL-17A --- HLA-DQB1*02 --- screening --- first-degree relatives --- non-celiac gluten sensitivity --- irritable bowel disease --- FODMAP --- wheat allergy --- vitamin B12 --- iron --- folic acid --- vitamin D --- long-term GFD therapy (LTGFD) --- LTGFD with good compliance (LTGFDWGC) --- anemia --- lymphoma --- IgA deficiency --- gut --- enteropathy --- gluten-free diet --- level of evidences --- gluten-related disorders --- NCGS --- self-report --- survey studies

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The incidence of gluten-related disorders (GRDs) continues to increase and its global prevalence is estimated affect to 5% of the population. s. Celiac disease (CD), Dermatitis Herpetiformis (DH), Gluten Ataxia (GA), wheat allergy (WA), and Non-Celiac Gluten Sensitivity (NCGS) are the five major GRDs that present with a wide range of clinical manifestations. They are manifested by symptoms of gastrointestinal tract disorders, as well as hematological, dermatological endocrinological, gynecological, rheumatological and nervous system. NCGS is a term that is used to describe individuals who are not affected by celiac disease or wheat allergy, yet they have intestinal and/or extra-intestinal symptoms related to gluten ingestion with improvement of their symptoms upon withdrawing gluten from their diet. It is believed that represents some heterogeneous groups with different subgroups characterized by different etiologies, clinical histories and clinical courses. There also appears to be an overlap between NCGS and irritable bowel syndrome (IBS). There is a need for establishing strict criteria for diagnosing NCGS. The absence of validated biomarkers remains a significant limitation for research studies on NCGS. New evidence shows that a gluten-free diet may be beneficial for some patients with gastrointestinal symptoms, such as those symptoms commonly found in patients with IBS.

celiac disease --- children --- HLA-DQ --- prevalence --- Asia --- wheat --- gluten --- non-celiac gluten-sensitivity --- diagnosis --- dermatitis herpetiformis --- anti-tTG --- anti-DGP --- AAA --- AGA --- IL-17A --- HLA-DQB1*02 --- screening --- first-degree relatives --- non-celiac gluten sensitivity --- irritable bowel disease --- FODMAP --- wheat allergy --- vitamin B12 --- iron --- folic acid --- vitamin D --- long-term GFD therapy (LTGFD) --- LTGFD with good compliance (LTGFDWGC) --- anemia --- lymphoma --- IgA deficiency --- gut --- enteropathy --- gluten-free diet --- level of evidences --- gluten-related disorders --- NCGS --- self-report --- survey studies --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The only effective and safe treatment of celiac disease (CD) is a lifelong, strict exclusion of gluten, the so-called gluten-free diet (GFD). As a consequence, strict adherence to the GFD is highly successful and useful to achieve optimal control of symptoms in celiac patients, although, sometimes, nutritional problems can persist despite a strict exclusion of gluten. However, following a strict GFD is not easy and an updated quality assessment of available products is needed for further improvement in gluten-free product development. Similar to CD, GFD is the common dietary approach in non-celiac gluten/wheat sensitivity (NCGWS). NCGWS is another common gluten-related disorder without the diagnostic features of CD. Increasing interest in the association and interaction between irritable bowel syndrome (IBS), functional dyspepsia, and gluten-related disorders can expand our knowledge and understanding of the management of these disorders. In this respect, GFD is considered a therapeutic option in IBS and functional digestive disorders. New insights into the GFD are an exciting scientific challenge for researchers.

irritable bowel syndrome --- celiac disease --- nonceliac gluten/wheat sensitivity --- gluten-free diet --- AIDAI score --- amylase trypsin inhibitor --- non-celiac wheat sensitivity --- CD14 lymphocytes --- interleukin-1beta --- tumor necrosis factor-α --- non coeliac wheat sensitivity --- gluten --- FODMAPs --- functional dyspepsia --- Celiac disease --- iron deficiency without anemia --- dietary iron --- iron supplementation --- women --- refractory celiac disease --- remission --- nickel allergy --- allergic contact mucositis --- irritable bowel syndrome (IBS) --- low-nickel diet --- gluten-free products --- gluten containing products --- food composition database --- dietary reference intake --- prison diets --- irritable bowel disease --- FODMAP --- low FODMAP diet --- gluten free diet --- non-celiac gluten wheat sensitivity --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

We have entered a new era where some concepts of the complex community of microorganisms (microbiota comprising bacteria, fungi, viruses, bacteriophages and helminths) are being re-discovered and re-visited. Microbiota and human interaction is not new; they have shared a long history of co-existence. Nevertheless, the opportunities to understand the role of these microorganisms in human diseases and to design a potential treatment were limited. At present, thanks to development of innovative and cutting-edge molecular biological and microbiological technologies as well as clinical informatics and bioinformatics skills, microbiome application is moving into clinics. Approaches to therapy based on prebiotics, probiotics and lately on fecal microbiota transplantation has revolutionized medicine. Microbiota outnumbers our genes and is now regarded as another organ of the body. The gastrointestinal tract and gut microbiota display a well-documented symbiotic relationship. Disruption of intestinal microbiota homeostasis—called dysbiosis—has been associated with several diseases. Whether dysbiosis is a cause or consequence of disease initiation and progression still needs to be investigated in more depth. The aim of this book is to highlight recent advances in the field of microbiome research, which are now shaping medicine, and current approaches to microbiome-oriented therapy for gastrointestinal diseases. Dr. Rinaldo Pellicano Dr. Sharmila Fagoonee Guest Editors

Public health & preventive medicine --- Bacteroides ovatus --- Bifidobacterium adolescentis --- Dysbiosis --- Faecalibacterium prausnitzii --- Ruminococcus gnavus --- type 1 diabetes --- microbiota --- microbiome --- auto-immunity --- gut permeability --- gut --- IBS --- celiac disease --- enteropathy --- gluten --- therapy --- gut microbiota --- precision medicine --- Clostridium difficile --- inflammatory bowel disease --- ulcerative colitis --- irritable bowel disease --- metabolic syndrome --- gastric microbiota --- transient --- persistent --- culture --- sequencing --- Helicobacter pylori --- fecal microbiota transplantation --- feces donor --- fecal microbiota --- flow cytometry --- viability of bacteria --- next-generation sequencing --- culturing of fecal microbiota --- Alzheimer’s disease --- microbiota–gut–brain axis --- neurodegenerative disease --- intestinal flora --- necrotizing enterocolitis --- intestinal microbiology --- infant gut --- metabolomics --- IL-6 --- IL-8 --- IL-12p70 --- intestinal permeability --- zonulin --- gut virome --- steatosis --- cirrhosis --- hepatocellular carcinoma --- gastrointestinal --- technology --- high-throughput --- crohn’s disease --- mononuclear cells --- transient receptor potential channel --- pancreatic diseases --- acute pancreatitis --- chronic pancreatitis --- diabetes mellitus --- pancreatic ductal adenocarcinoma --- pancreatic cystic neoplasms

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

We have entered a new era where some concepts of the complex community of microorganisms (microbiota comprising bacteria, fungi, viruses, bacteriophages and helminths) are being re-discovered and re-visited. Microbiota and human interaction is not new; they have shared a long history of co-existence. Nevertheless, the opportunities to understand the role of these microorganisms in human diseases and to design a potential treatment were limited. At present, thanks to development of innovative and cutting-edge molecular biological and microbiological technologies as well as clinical informatics and bioinformatics skills, microbiome application is moving into clinics. Approaches to therapy based on prebiotics, probiotics and lately on fecal microbiota transplantation has revolutionized medicine. Microbiota outnumbers our genes and is now regarded as another organ of the body. The gastrointestinal tract and gut microbiota display a well-documented symbiotic relationship. Disruption of intestinal microbiota homeostasis—called dysbiosis—has been associated with several diseases. Whether dysbiosis is a cause or consequence of disease initiation and progression still needs to be investigated in more depth. The aim of this book is to highlight recent advances in the field of microbiome research, which are now shaping medicine, and current approaches to microbiome-oriented therapy for gastrointestinal diseases. Dr. Rinaldo Pellicano Dr. Sharmila Fagoonee Guest Editors

Public health & preventive medicine --- Bacteroides ovatus --- Bifidobacterium adolescentis --- Dysbiosis --- Faecalibacterium prausnitzii --- Ruminococcus gnavus --- type 1 diabetes --- microbiota --- microbiome --- auto-immunity --- gut permeability --- gut --- IBS --- celiac disease --- enteropathy --- gluten --- therapy --- gut microbiota --- precision medicine --- Clostridium difficile --- inflammatory bowel disease --- ulcerative colitis --- irritable bowel disease --- metabolic syndrome --- gastric microbiota --- transient --- persistent --- culture --- sequencing --- Helicobacter pylori --- fecal microbiota transplantation --- feces donor --- fecal microbiota --- flow cytometry --- viability of bacteria --- next-generation sequencing --- culturing of fecal microbiota --- Alzheimer’s disease --- microbiota–gut–brain axis --- neurodegenerative disease --- intestinal flora --- necrotizing enterocolitis --- intestinal microbiology --- infant gut --- metabolomics --- IL-6 --- IL-8 --- IL-12p70 --- intestinal permeability --- zonulin --- gut virome --- steatosis --- cirrhosis --- hepatocellular carcinoma --- gastrointestinal --- technology --- high-throughput --- crohn’s disease --- mononuclear cells --- transient receptor potential channel --- pancreatic diseases --- acute pancreatitis --- chronic pancreatitis --- diabetes mellitus --- pancreatic ductal adenocarcinoma --- pancreatic cystic neoplasms --- Bacteroides ovatus --- Bifidobacterium adolescentis --- Dysbiosis --- Faecalibacterium prausnitzii --- Ruminococcus gnavus --- type 1 diabetes --- microbiota --- microbiome --- auto-immunity --- gut permeability --- gut --- IBS --- celiac disease --- enteropathy --- gluten --- therapy --- gut microbiota --- precision medicine --- Clostridium difficile --- inflammatory bowel disease --- ulcerative colitis --- irritable bowel disease --- metabolic syndrome --- gastric microbiota --- transient --- persistent --- culture --- sequencing --- Helicobacter pylori --- fecal microbiota transplantation --- feces donor --- fecal microbiota --- flow cytometry --- viability of bacteria --- next-generation sequencing --- culturing of fecal microbiota --- Alzheimer’s disease --- microbiota–gut–brain axis --- neurodegenerative disease --- intestinal flora --- necrotizing enterocolitis --- intestinal microbiology --- infant gut --- metabolomics --- IL-6 --- IL-8 --- IL-12p70 --- intestinal permeability --- zonulin --- gut virome --- steatosis --- cirrhosis --- hepatocellular carcinoma --- gastrointestinal --- technology --- high-throughput --- crohn’s disease --- mononuclear cells --- transient receptor potential channel --- pancreatic diseases --- acute pancreatitis --- chronic pancreatitis --- diabetes mellitus --- pancreatic ductal adenocarcinoma --- pancreatic cystic neoplasms